Physician profile
Daniel Taheri
NPI 1992774681
$12,248.13
in general payments reported to CMS, 2019-2025
18 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $122 · 2021: $262 · 2022: $685 · 2023: $9,892 · 2024: $74.76 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Travel and Lodging: $1,498 · Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Travel and Lodging | $1,498.15 |
| Food and Beverage | $815.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $9,740.89 | 2022-2023 | Odomzo |
| Merz North America, INC. | $969.39 | 2019-2022 | |
| Allergan, INC. | $471.46 | 2019-2022 | |
| Abbvie INC. | $244.22 | 2021-2025 | Botox, Skyrizi |
| Galderma Laboratories, L.P. | $177.29 | 2019-2025 | Dysport |
| Regeneron Healthcare Solutions, INC. | $149.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.46 | 2020-2023 | |
| Janssen Biotech, INC. | $80.96 | 2021 | |
| Pfizer INC. | $73.09 | 2025 | |
| Sensus Healthcare, INC. | $46.34 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $36.05 | 2020 | |
| Biofrontera INC. | $31.14 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $29.56 | 2024 | Otezla |
| Tactile Systems Technology INC | $26.32 | 2021 | |
| Dusa Pharmaceuticals, INC. | $20.00 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $14.83 | 2020 | |
| Prugen, INC. Pharmaceuticals | $13.33 | 2020 | |
| Leo Pharma INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Taheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.